quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:30:35·43d
INSIDERFiling
Relay Therapeutics Inc. logo

SEC Form 4 filed by Relay Therapeutics Inc.

RLAY· Relay Therapeutics Inc.
Health Care
Full content unavailable. See the original source below.
Original source

Companies

  • RLAY
    Relay Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Jan 26UpdateOppenheimer$14.00
  • Dec 12UpdateWells Fargo$13.00
  • Sep 4UpdateGuggenheim$15.00
  • Apr 17UpdateWells Fargo$4.00
  • Sep 10UpdateGoldman$20.00
  • Sep 10UpdateOppenheimer-

Related

  • SEC7d
    SEC Form PRE 14A filed by Relay Therapeutics Inc.
  • SEC10d
    SEC Form SCHEDULE 13G filed by Relay Therapeutics Inc.
  • INSIDER14d
    SEC Form 4 filed by Catinazzo Thomas
  • PR21d
    Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026
  • SEC28d
    Amendment: SEC Form SCHEDULE 13G/A filed by Relay Therapeutics Inc.
  • SEC35d
    SEC Form SCHEDULE 13G filed by Relay Therapeutics Inc.
  • SEC39d
    Relay Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
  • PR39d
    Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022